[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100518892":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":32,"centralContacts":36,"locations":45,"responsibleParty":76,"collaborators":40,"id":78,"slug":79,"hasResults":80,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":86,"sex":87,"minAge":88,"maxAge":89,"enrollmentInfo":90,"targetDuration":40,"studyType":93,"phases":94,"briefSummary":96,"conditions":97,"keywords":99,"overallStatus":48,"whyStopped":40,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":115},{"fullName":5,"class":6},"Thomas Jefferson University","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Cerclage","EXPERIMENTAL","Cervical cerclage placement with removal during the 36th week of gestation or earlier if clinically indicated.",[13,14],"Procedure: Cervical cerclage","Drug: Vaginal Suppository Progesterone",{"label":16,"type":6,"description":17,"interventionNames":18},"Control","Continuing or initiation of vaginal progesterone 200mg daily until 36 weeks of gestation.",[14],[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"PROCEDURE","Cervical cerclage","Transvaginal cervical cerclage placed between 24 0\u002F7 - 26 6\u002F7 weeks of gestation.",[9],[9],{"type":27,"name":28,"description":17,"armGroupLabels":29,"otherNames":30},"DRUG","Vaginal Suppository Progesterone",[9,16],[31],"Vaginal progesterone",[33],{"name":34,"affiliation":5,"role":35},"Moti Gulersen, MD, MSc","PRINCIPAL_INVESTIGATOR",[37,42],{"name":34,"role":38,"phone":39,"phoneExt":40,"email":41},"CONTACT","215-955-5000",null,"moti.gulersen@jefferson.edu",{"name":43,"role":38,"phone":39,"phoneExt":40,"email":44},"Vincenzo Berghella, MD","vincenzo.berghella@jefferson.edu",[46,65],{"facility":47,"status":48,"city":49,"state":50,"zip":51,"country":52,"countryCode":53,"cosmosGeoPoint":54,"geoPoint":59,"contacts":60},"Atrium Health Carolinas Medical Center","RECRUITING","Charlotte","North Carolina","28204","United States","US",{"type":55,"coordinates":56},"Point",[57,58],-80.84313,35.22709,{"lat":58,"lon":57},[61],{"name":62,"role":38,"phone":63,"phoneExt":40,"email":64},"Lorene Temming, MD, MSCI","704-448-0305","Lorene.Temming@advocatehealth.org",{"facility":5,"status":48,"city":66,"state":67,"zip":68,"country":52,"countryCode":53,"cosmosGeoPoint":69,"geoPoint":73,"contacts":74},"Philadelphia","Pennsylvania","19107",{"type":55,"coordinates":70},[71,72],-75.16362,39.95238,{"lat":72,"lon":71},[75],{"name":34,"role":38,"phone":39,"phoneExt":40,"email":41},{"type":77,"investigatorFullName":40,"investigatorTitle":40,"investigatorAffiliation":40,"oldNameTitle":40,"oldOrganization":40},"SPONSOR","100518892","late-cerclage-in-high-risk-pregnancies-latch-100518892",false,"NCT06036446","LATe Cerclage in High-risk Pregnancies (LATCH)","Cervical Cerclage for Short Cervix at 24-26 Weeks of Gestation: a Randomized Controlled Trial","LATCH","Inclusion Criteria:\n\n* 18-50 years old, pregnant, assigned female at birth\n* Singleton pregnancy\n* TVU CL ≤25mm between 24 0\u002F7 - 26 6\u002F7 weeks of gestation\n\nExclusion Criteria:\n\n* Initial multifetal gestation with subsequent multifetal pregnancy reduction, or selective fetal termination performed \\>14 weeks, or cotwin pregnancy loss diagnosed \\>14 weeks\n* Cerclage in situ\n* Preterm labor, defined as painful regular uterine contractions and change in cervical dilation\n* PPROM\n* Active vaginal bleeding\n* Suspected intraamniotic infection\n* Major fetal structural abnormality or chromosomal disorder\n* Placenta previa or accreta\n* Other contraindication to cerclage placement\n* Participation in another clinical trial related to preterm birth prevention, cerclage, or progesterone",true,"FEMALE","18 Years","50 Years",{"count":91,"type":92},329,"ESTIMATED","INTERVENTIONAL",[95],"NA","The goal of this clinical trial is to determine whether cervical cerclage reduces the risk of preterm birth in patients with a short transvaginal ultrasound (TVU) cervical length (CL) ≤25mm between 24 0\u002F7-26 6\u002F7 weeks.",[98],"Premature Birth",[100,101,102,103,104,105],"Cervical length","Short cervix","Shortened cervix","Prematurity","Preterm birth","Viability","2026-05-27",{"date":108,"type":109},"2026-05-29","ACTUAL",{"date":111,"type":109},"2023-11-10",{"date":113,"type":92},"2029-02",{"name":5,"class":6},2]